Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) Short Interest Up 465.0% in June

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) saw a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 226 shares, a growth of 465.0% from the June 15th total of 40 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 1,898 shares, the days-to-cover ratio is currently 0.1 days.

Orion OYJ Price Performance

Shares of ORINY stock remained flat at $38.86 during mid-day trading on Friday. 132 shares of the stock traded hands, compared to its average volume of 518. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.77 and a quick ratio of 1.13. The company has a 50-day simple moving average of $38.36 and a 200 day simple moving average of $38.62. Orion OYJ has a 1 year low of $30.89 and a 1 year high of $42.75. The stock has a market capitalization of $10.97 billion, a P/E ratio of 17.82 and a beta of 0.08.

Orion OYJ (OTCMKTS:ORINY) last announced its quarterly earnings results on Thursday, April 23rd. The company reported $0.37 earnings per share (EPS) for the quarter. Orion OYJ had a net margin of 27.14% and a return on equity of 49.17%. The company had revenue of $488.80 million for the quarter.

About Orion OYJ

Orion Corporation (Orion Oyj) is a Finland-based pharmaceutical company engaged in the research, development, manufacture and marketing of human and veterinary medicines as well as diagnostic tests. The company’s core therapeutic areas include central nervous system disorders, oncology and respiratory diseases, and it offers both proprietary and generic products. Orion’s product range spans from small-molecule drugs and active pharmaceutical ingredients to radiodiagnostic imaging agents and line extensions developed through in-house research.

Since its founding in 1917 in Helsinki, Orion has grown into an integrated pharmaceuticals business with state-of-the-art manufacturing facilities in Finland and France.